Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8

specific

Stage IV includes: IVA: (T4a, N1-2, M0); (T4a, NX, M0); (T4b, N0-2, M0); (Any T, N3, M0); IVB: (Any T, Any N, M1). T4a: Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum. T4b: Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway. NX: Regional lymph nodes cannot be assessed. N0: No regional lymph node metastasis. N1: Tumor with metastasis in one or two regional lymph nodes. N2: Tumor with metastasis in three to six regional lymph nodes.

13

Centers

14

Active Trials

Cancer Funding

Top Centers for Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8(13)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
High-Volume Research Center
74.6
2
NCI Comprehensive
Active Research Program
52.1
3
NCI Comprehensive
Active Research Program
52.1
4
NCI Comprehensive
Active Research Program
52.1
552.1
6
NCI Comprehensive
Active Research Program
52.1
7
NCI Comprehensive
Active Research Program
52.1
8
Active Research Program
52.1
9
NCI Comprehensive
Active Research Program
52.1
10
NCI Clinical
Active Research Program
52.1
11
Active Research Program
52.1
12
Active Research Program
52.1
13
Active Research Program
52.1

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →